RECRUITING

MRI and Biomarkers for Lung Nodules Detected During Lung Cancer Screening

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary objective of this pilot observational study is to evaluate the accrual and retention rate of a study population from a centralized lung cancer screening program to support MRI and blood-based biomarker research for lung cancer screening.

Official Title

A Pilot Study Evaluating the Feasibility of Novel MRI Sequences and Blood-Based Biomarkers for Discriminating Nodules Found During Lung Cancer Screening

Quick Facts

Study Start:2023-06-27

Study Completion:2026-08-27

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05699213

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Ability to read and understand informed consent * Male or female adults who are at high risk for lung cancer and are enrolled in the centralized lung cancer screening program: Based on USPSTF guidelines: Age 50-80 with 20 or greater pack-year smoking story who continue to smoke or quit within the past 15 years without sign or symptoms of lung cancer. Or based on National Comprehensive Cancer Network (NCCN) guidelines but do not meet the USPSTF guidelines, age 50-unlimited * Found to have one or more lung nodules that is 6mm or greater on screening LDCT	* Persons with an active diagnosis of cancer * Persons with active signs or symptoms of lung cancer * Persons with mechanically, magnetically, or electrically activated implants, such as cardiac pacemakers, neurostimulators, and infusion pumps. * Persons with ferromagnetic implants and ferromagnetic foreign bodies, such as intracranial aneurysm clips, shrapnel and intraocular metal chips as these could become dislodged. * Persons who are pregnant, nursing, are implanted with intrauterine devices (IUD's) that are not MR-compatible * Persons unable to tolerate MRI imaging secondary to an inability to lie supine or severe claustrophobia. * Persons who are non-compliant with visit instructions, including inability to lie still, hold breath or follow procedure instructions

Inclusion Criteria

Exclusion Criteria

* Ability to read and understand informed consent
* Male or female adults who are at high risk for lung cancer and are enrolled in the centralized lung cancer screening program: Based on USPSTF guidelines: Age 50-80 with 20 or greater pack-year smoking story who continue to smoke or quit within the past 15 years without sign or symptoms of lung cancer. Or based on National Comprehensive Cancer Network (NCCN) guidelines but do not meet the USPSTF guidelines, age 50-unlimited
* Found to have one or more lung nodules that is 6mm or greater on screening LDCT

* Persons with an active diagnosis of cancer
* Persons with active signs or symptoms of lung cancer
* Persons with mechanically, magnetically, or electrically activated implants, such as cardiac pacemakers, neurostimulators, and infusion pumps.
* Persons with ferromagnetic implants and ferromagnetic foreign bodies, such as intracranial aneurysm clips, shrapnel and intraocular metal chips as these could become dislodged.
* Persons who are pregnant, nursing, are implanted with intrauterine devices (IUD's) that are not MR-compatible
* Persons unable to tolerate MRI imaging secondary to an inability to lie supine or severe claustrophobia.
* Persons who are non-compliant with visit instructions, including inability to lie still, hold breath or follow procedure instructions

Contacts and Locations

Study Contact

Weijia Chua, MD

CONTACT

310-423-1838

weijia.chua@cshs.org

Principal Investigator

Sara Ghandehari, MD

PRINCIPAL_INVESTIGATOR

Cedars-Sinai

Study Locations (Sites)

Cedars-Sinai Medical Center

Los Angeles, California, 90048

United States

Collaborators and Investigators

Sponsor: Cedars-Sinai Medical Center

Sara Ghandehari, MD, PRINCIPAL_INVESTIGATOR, Cedars-Sinai

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-06-27

Study Completion Date2026-08-27

Study Record Updates

Study Start Date2023-06-27

Study Completion Date2026-08-27

Terms related to this study

Additional Relevant MeSH Terms

Lung Cancer